Skip to Content

Journal

Find a Doctor


To search Houston doctors, please select a specialty & submit your Zip Code below.

Advanced Search
Search by Doctor's Name

Schedule Now

Ongoing Clinical Trials

A Phase 2 Study of Androgen Deprivation Therapy plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer

Researchers are assessing the clinical benefit of androgen deprivation therapy (ADT) plus chemotherapy in previously untreated patients with local failures, or patients who were not candidates for prostatectomy or radiation therapy. By treating all components of the tumor initially, they anticipate that androgen-independent growth will be delayed, prolonging patient survival. Patient subsets are designed to ensure that fewer hormones are used in those with more favorable parameters; patients with more aggressive disease will receive 1-2 extra cycles of chemotherapy. The drugs used in this study are FDA approved.

Lead Physician: Robert J. Amato, D.O.

Contact: Christine Kent, RN, at 832.325.6515 or christine.m.kent@uth.tmc.edu

A Phase 2 Trial of Pembrolizumab in Subjects with Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy

The purpose of this study is to test the safety, tolerability and effectiveness of pembrolizumab (MK-3475) for the treatment of patients with advanced prostate cancer who were previously treated with other chemotherapy. MK-3475 has been approved for use in certain types of skin cancer called malignant melanoma; however, it has not been approved by the FDA for the treatment of prostate cancer.

Lead Physician:Robert J. Amato, D.O.

Contact: Christine Kent, RN, at 832.325.6515 or christine.m.kent@uth.tmc.edu

A Phase 3 Randomized, Placebo-controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-risk Hormone Receptor-positive and Her2/Neu Negative Breast Cancer

In this study researchers are assessing whether treatment with everolimus plus hormone treatment after chemotherapy will increase the length of time patients remain cancer free. The current standard treatment after chemotherapy is hormone treatment alone. Everolimus is currently approved for the treatment of patients with advanced or metastatic kidney or breast cancer. It is considered investigational for non-metastatic breast cancer patients. In this study participants will get hormone treatment with either everolimus or with placebo. The combination of hormone-treatment and everolimus is experimental in patients with breast cancer.

Lead Physician:Anneliese Gonzalez, M.D.
Contact: Cheri Klingner, B.S.N., RN, CCRP, at 832.325.7710 or katherine.c.klingnerwinton@uth.tmc.edu